⌕
Viking Therapeutics · VKTX · Nasdaq
Tenet 36 · Weak
Compare
$26.88+0.30%At closeTenet 36 · Weak
$26.88+0.08 (+0.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Viking Therapeutics (VKTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+45.9%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼227.1%
−359.6
FY21→FY25CAGR —
Diluted EPS▼215.8%
−3.19
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+45.9%

77.2mn → 112.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−345.0R&D−48.4SG&A−393.3Op income33.7Tax & other−359.6Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
586,166.0344,955.0101,644.063,806.054,234.044,981.0▲239.4%+66.4%
Selling, general & admin
62,406.048,387.049,277.037,021.016,121.010,701.0▼1.8%+45.8%
Total operating expenses
648,572.0393,398.0151,015.0100,915.070,414.055,700.0▲160.5%+63.0%
Operating incomefeeds ROC rank
−648,572.0−393,342.0−150,921.0−100,827.0−70,355.0−55,682.0▼160.6%—
Other income, net
21,377.033,759.041,052.015,020.01,547.0710.0——
Pretax income
−627,195.0−359,583.0−109,869.0−85,807.0−68,808.0−54,972.0▼227.3%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−627,195.0−359,639.0−109,963.0−85,895.0−68,867.0−54,990.0▼227.1%—
Per share
Diluted EPSbuyback-sensitive
−5.41−3.19−1.01−0.91−0.90−0.71▼215.8%—
Diluted shares (mn)
118.05112.67109.0494.3576.8377.20▲3.3%+9.9%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY14 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-11 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.